Predictors of outcome after short-term stabilization with buprenorphine

Journal of Substance Abuse Treatment

Volumn 44, Issue 3, 2013, Pages 336-342

  Hillhouse, Maureen ^a   Canamar, Catherine P ^a   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Detoxification; Opiates; Opioid; Predictors

Indexed keywords

BUPRENORPHINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DEPRESSION; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG USE; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTIPLE DRUG ABUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGE FACTORS; BUPRENORPHINE; CRIME; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872271131     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2012.08.016     Document Type: Article

References (30)

1. Amass L., Kamien J.B., Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 2000, 58:143-152.
2. Amato L., Davoli M., Minozzi S., Ali R., Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2005, CD003409.
3. Amato L., Minozzi S., Davoli M., Vecchi S., Ferri M.M., Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews 2008, CD005031.
4. Awgu E., Magura S., Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. Journal of Psychoactive Drugs 2010, 42:339-346.
5. Berman A.H., Kallmen H., Barredal E., Lindqvist P. Hopeless patients? A study of illicit opiate users who drop out from in-patient detoxification. Journal of Substance Use 2007, 13:121-130.
6. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics 1988, 43:72-78.
7. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. Journal of Pharmacology and Experimental Therapeutics 1988, 247:47-53.
8. Blondell R.D., Smith S.J., Servoss T.J., DeVaul S.K., Simons R.L. Buprenorphine and methadone: A comparison of patient completion rates during inpatient detoxification. Journal of Addictive Diseases 2007, 26:3-11.
9. Childress A.R., McLellan A.T., O'Brien C.P. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. British Journal on Addictions 1986, 81:655-660.
10. Cropsey K.L., Lane P.S., Hale G.J., Jackson D.O., Clark C.B., Ingersoll K.S., et al. Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug and Alcohol Dependence 2011, 119:172-178.
11. Dunn K.E., Sigmon S.C., Strain E.C., Heil S.H., Higgins S.T. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. Drug and Alcohol Dependence 2011, 119:1-9.
12. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. American Journal on Addictions 2008, 17:116-120.
13. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence 2004, 75:37-45.
14. Hillhouse M.P., Marinelli-Casey P., Gonzales R., Ang A., Rawson R.A. Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. Addiction 2007, 102(Suppl. 1):84-95.
15. Kaplan R.F., Cooney N.L., Baker L.H., Gillespie R.A., Meyer R.E., Pomerleau O.F. Reactivity to alcohol-related cues: Physiological and subjective responses in alcoholics and nonproblem drinkers. Journal of Studies on Alcohol 1985, 46:267-272.
16. Lanier R.K., Umbricht A., Harrison J.A., Nuwayser E.S., Bigelow G.E. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: An open-label evaluation. Psychopharmacology 2008, 198:149-158.
17. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005, 100:1090-1100.
18. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998, 93:475-486.
19. Ling W., Hillhouse M., Domier C., Doraimani G., Hunter J., Thomas C., et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009, 104:256-265.
20. Magura S., Nwakeze P.C., Demsky S.Y. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998, 93:51-60.
21. Marsch L.A., Stephens M.A., Mudric T., Strain E.C., Bigelow G.E., Johnson R.E. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental and Clinical Psychopharmacology 2005, 13:293-302.
22. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., et al. New data from the Addiction Severity Index. Reliability and validity in three centers. Journal of Nervous and Mental Disorders 1985, 173:412-423.
23. Poirier M.F., Laqueille X., Jalfre V., Willard D., Bourdel M.C., Fermanian J., et al. Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: Results of a multicenter study of 73 patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28:267-272.
24. Sigmon S.C., Dunn K.E., Badger G.J., Heil S.H., Higgins S.T. Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study. Addictive Behaviors 2009, 34:304-311.
25. Simpson D.D., Joe G.W., Rowan-Szal G.A. Drug abuse treatment retention and process effects on follow-up outcomes. Drug and Alcohol Dependence 1997, 47:227-235.
26. Springer S.A., Chen S., Altice F.L. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of buprenorphine treatment. Journal of Urban Health 2010, 87:592-602.
27. Stein M.D., Cioe P., Friedmann P.D. Buprenorphine retention in primary care. Journal of General Internal Medicine 2005, 20:1038-1041.
28. Wang E.A., Moore B.A., Sullivan L.E., Fiellin D.A. Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. Journal of General Internal Medicine 2010, 25:670-674.
29. Wesson D.R., Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 2003, 35:253-259.
30. Wesson D.R., Smith D.E. Buprenorphine in the treatment of opiate dependence. Journal of Psychoactive Drugs 2010, 42:161-175.